Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep ( (IMMP) ) has issued an update.
Immutep Limited has released its quarterly activities report for Q1 FY26, highlighting significant progress in its clinical trials and financial position. The company is advancing its pivotal TACTI-004 Phase III trial for eftilagimod alfa in non-small cell lung cancer, with over 100 clinical sites now open for enrollment across 24 countries. Additionally, Immutep received positive feedback from the FDA for its head and neck cancer program and launched a new Phase II trial for breast cancer. The company maintains a strong financial position with A$109.85 million in cash, ensuring operations through the end of 2026.
The most recent analyst rating on (IMMP) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. However, positive technical indicators provide some optimism, suggesting potential short-term bullish momentum. The valuation remains unattractive due to negative earnings and the absence of dividends.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep Limited is a late-stage immunotherapy company focused on developing treatments for cancer and autoimmune diseases. The company is known for its pioneering work with eftilagimod alfa (efti), a first-in-class MHC Class II agonist, and its ongoing efforts in targeting immune checkpoints to enhance the body’s immune response against tumors.
Average Trading Volume: 123,037
Technical Sentiment Signal: Buy
Current Market Cap: $290.7M
Find detailed analytics on IMMP stock on TipRanks’ Stock Analysis page.